海吉亚医疗(06078.HK)急涨近15%重越百天线 全年多赚逾3倍末期息12分
去年6月才以每股18.5元来港上市的内地最大肿瘤医疗集团海吉亚医疗(06078.HK)公布全年多赚逾3倍末期股息12分,该股扭转昨天回软势,今早重越10天、20天及100天线(49.4-54.9元),最高见56.95元,现造55元,急涨14.6%,成交倍增至181万股。
海吉亚公布,去年纯利按年升近3.3倍至1.7亿元人民币(下同),每股盈利38分,末期股息12分。期内,总营收按年升29%至14.02亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.